ABSTRACT
Background: Vernal keratoconjunctivitis (VKC) is a recurrent, bilateral, external, ocular inflammation primarily affecting young adults living in warm dry climates. The objectives of the research was to compare the two ophthalmic solutions of olopatadine hydrochloride (0.1%) and epinastine hydrochloride (0.05%) on clinical signs of vernal keratoconjuntivitis and to determine side effects of both the drugs.Methods: The study was carried out in 40 patients who attended the out-patient department (OPD) Ophthalmology, Darbhanga Medical College and Hospital, Laheriasarai from July 2007 to December 2008. Forty patients with symptoms of VKC (ocular itching, ropy discharge, papillary hypertrophy, gelatinous thickening and horner-trantas spots were selected and included in our study.Results: Mean score of palpebral hyperemia at 0, 14, 28 and 42 days in olopatadine treated eye were 2.1, 1.4, 0.8 and 0.4 respectively having p value <0.01, and <0.01 and <0.05 respectively, while mean score at same stages in placebo eye were 2.1, 2, 1.9, and 1.5 having value >0.05. Epinastine treated group mean score of palpebral hyperemia were <0.01 and <0.01 respectively in epinastine treated eye whereas in placebo treated eye, mean score were 2.1, 2.0, 1.8 and 1.6 respectively having p value >0.05 in all stages. Statistically insignificant reduction at day 14 while very significant reduction at day 28 and 42 was observed in epinastine treated eye as compared to placebo.Conclusions: The present study had shown that both olopatadine and epinastine were effective in treating clinical signs of VKC as compared to placebo.
ABSTRACT
Aims: To formulate fast dissolving tablets of amlodipine besylate using co-processed superdisintigrant and evaluate the properties of fast dissolving tablets. Study Design: Formulation, evaluation of fast dissolving tablets of amlodipine besylate. Place and Duration of Study: Department of Quality Assurance S. N. D. College of Pharmacy Babhulgoan Yeola Dist Nashik 423401, between July 2012 to February 2013. Methodology: In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and sodium starch glycolate in different ratios (1:1, 1:2 1:3 2:1, 3:1) in the fast dissolving tablet formulations. Drug and the developed excipients were characterized for compatibility studies with FTIR and DSC. The co-processed superdisintigrant mixture was evaluated for angle of repose, Carr’s index and Hausner’s ratio in comparison with physical mixture of superdisintegrants. Fast dissolving tablets of Amlodipine Besylate were prepared using co-processed superdisintegrants and evaluated for pre-compression and postcompression parameters. Effect of co-processed superdisintegrants (crospovidone and sodium starch glycolate) on wetting time, disintegrating time, drug content, in-vitro release, and stability parameters have been studied. Results: The angle of repose of the developed excipients was found to be < 300 Compressibility (%) index in the range of 13.14 to 14.63 % and Hausner’s ratio in the range of 1.15-1.19. The prepared tablets were characterized by FTIR and DSC Studies there was no change in the result. Based on in-vitro dispersion time (approximately 40 sec), promising formulation CP5 was tested for in-vitro drug release pattern in phosphate buffer pH 6.8. Conclusion: Among the designed formulations, the formulation (CP5) containing coprocessed superdisintegrant (3:1 mixture of crospovidone and sodium starch glycolate) emerged as the overall best formulation based on drug release characteristics in phosphate buffer pH 6.8. From this study, it can be concluded that dissolution rate of amlodipine besylate could be enhanced by tablets containing co-processed superdisintegrant.